Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
20 févr. 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
30 janv. 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Synlogic Announces Participation in Upcoming Investor and Industry Conferences
24 janv. 2023 06h57 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the...
Synlogic To Present at Upcoming Investor and Industry Conferences
08 févr. 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
aTyr Pharma to Present at BIO CEO & Investor Conference
07 févr. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
06 janv. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
21 déc. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on...
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
13 déc. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update
15 nov. 2021 08h00 HE
|
Galectin Therapeutics Inc.
Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning...
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
05 nov. 2021 16h24 HE
|
Galectin Therapeutics Inc.
New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis:...